Hero

Celyad announces new agreements with Celdara Medical and Dartmouth College

1

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces initiation of the SHRINK trial

2

Celyad announces initiation of the SHRINK trial

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

3

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

4

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

5

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

More info about Celyad

Latest News

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces new agreements with Celdara Medical and Dartmouth College

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Information on the total number of voting rights and shares (Articles 15 of the Law of 2 May 2007)

Celyad announces initiation of the SHRINK trial

Celyad announces initiation of the SHRINK trial

Discover all news

Carousel

Social Feed